MEDSCHOOL, MED, Research, Translational Medicine Unit (TMU) - What We Do

CURRENTLY ENROLLING STUDIES

We are enrolling volunteers for the following study and preparing for additional studies that will open in the coming months. If you are interested in participating in clinical research at the TMU, please call (202) 819-6482, email clinical.research.unit.53-ggg@usuhs.edu, or fill out the TMU Study Interest Form to be contacted at a later date.

SC2i (TDAP) is currently enrolling healthy volunteers to donate blood for an IRB-approved research protocol.

Joining the TMU Registry allows our clinical team to contact you about upcoming studies that match your interests. It does not enroll you in a clinical trial or obligate you to participate. If you choose to explore a specific study, you will be asked to complete a separate eligibility screening and formal informed consent process before participating. 

UPCOMING STUDIES

RION MiRROR– Achilles Tendinopathy will enroll adults with Achilles tendinopathy. The study will evaluate the safety and tolerability of an investigational Purified Exosome Product (PEP) administered by injection in the tendon.

KET-112 will enroll healthy adult volunteers and compare an investigational ketamine nasal spray with intravenous ketamine to evaluate pharmacokinetics and analgesic effects.

Defense Blue will be conducted in coordination with SOCOM and DARPA. The study will evaluate Oxafence, a light-activated product containing methylene blue, to assess whether pathogens on full military uniforms can be inactivated. This study will not require participant enrollment.

SOLACE – Burn Project is being developed in collaboration with MedStar with 40-70 planned participants.  Additional study details will be available as the protocol is finalized.

Lab Sample Study is an investigator-led study with the TMU providing research and laboratory support. Expected to enroll approximately 20 participants, the study utilizes the TMU for sample collection and phlebotomy services. This collaboration reflects the TMU’s broader mission to support investigator-initiated protocols and advance clinical research capabilities.

LASSA (Phase 1): A first-in-human, randomized, double-blind, placebo-controlled, dose-escalation study assessing the safety, tolerability, and immunogenicity of an investigational Lassa virus vaccine in healthy adults.

Moderna Myocarditis: Protocol development and cross-institutional coordination with Moderna are underway. Comprehensive study parameters will be released upon finalization of the protocol, data agreements, and site activities.

CLOSED STUDIES

COVIVA(Clinical Trial ID NCT0548117) has completed participant enrollment for its study evaluating postural orthostatic tachycardia syndrome (POTS) symptoms. The study team is currently conducting final study visits with enrolled participants. Study updates are provided directly to enrolled volunteers, and broader trial findings will be published as final data become available.